Find Best Dentist

Recent clinical technology have made HIV/AIDS a highly manageable disease. Well-suited medical care can sustain the lives of HIV-infected persons and prevent unwanted and conceivably expensive aggravations. However, not all HIV-infected individuals have sufficient access to medical care.  Given the economic downturn across the US, budget cuts is not surprising. However, this fact doesn’t lessen the pain of the $85 million budget slash aimed at AIDS programs across California. Hardest hit in the cuts are HIV education and prevention programs, testing and counseling services, home services and early intervention services. The Governor has accepted the difficult decision to cut AIDS programs. Spending on health care breeds economic activity, supports jobs, and produces income as it “surges” through the economy, and becomes greater than the actual amount spent. Economists call this phenomenon a “multiplier effect”. Good example is, recent study estimated that million in state spending on social program in California generates about ,000 in sales taxes that go back to the state and local governments. Contrariwise, when spending on health care is cut, it has a negative economic impact that is even greater than the amount cut. This impact is further aggravated because the additio n of federal funding creates a significant increase in purchasing power. Therefore, when health care spending is cut, the effects [resonate/oscillates/reverberates] throughout the economy.

California’s most vulnerable population has its services on the chopping block again in the latest round of proposed state budget cuts. Needy families counting on welfare and Medi-Cal, children of low-income families, and individuals suffering from HIV or AIDS were all part of Gov. Arnold Schwarzenegger’s May budget revise reductions. The proposal also includes to stop all general fund contributions to up to 220 state parks, which could include the La Purisima Mission and parks along the Gaviota Coast. The governor’s proposed elimination of the CalWorks program is expected to affect 3,500 families in Sta. Barbra County as reported by Kathy Gallagher, the director of the County Social Services Department. The CalWORKs program provides temporary financial help and employment focused services to families with minor children who have income and property below State maximum limits for their family size. Most able-bodied aided parents are also required to participate in the CalWORKs GAIN employment services program. Abiding to the proposed budget cuts would make California the only state and the first world country of civilized nations in the world to not have a catch program for the poor families.  Dissolving the welfare program, which gives cash aid and services to qualified impoverish California families, would placing the load directly on the county, making such idea totally wild.

The  planned reduction of  the state’s general fund contribution to AIDS Drug Assistance Program (ADAP) and other AIDS services, including counseling, testing and home-based care, would also result to widespread HIV infections and deaths.Each year in California, an estimated 5,000 to 7,000 people become infected. About one in five do not know they have the infection. California has one of the highest infection rates in the U.S. with more than 100,000 people living with HIV/AIDS, according to the California Department of Public Health Office of AIDS.   The state´s ability to identify people living with HIV/AIDS is now severely paralyzed—creating an gigantic obstacle to the prevention of new infections and linking those who need it to treatment. Not only will the Governor´s apathetic funding cuts ravage those living with HIV/AIDS who rely on the services the state provides to stay alive and healthy, but today’s cuts also pose a serious threat to our shared responsibility to combat the spread of HIV in California.

The availability of HAART since 1996 has had a dramatic effect on the face of AIDS HIV. HAART is a customized combination of different classes of medications that a physician prescribes based on such factors as the patient’s viral load, CD4⁺ lymphocyte count, and clinical symptoms. CD4⁺ lymphocytes are white blood cells that HIV infects and kills, leading to a weakened immune system and AIDS. HAART is not a cure, it controls viral load, which helps to delay the symptoms and ultmately survive longer with HIV AIDS.

With HAART the medical implications that HIV has have been changed. Diagnoses of HIV OI’s and other complications have decreased sigificantly since its introduction. Other neurological problems associated with long term use of this therapy include nerve damage. HAART is also reported to be associated with increased lipid levels (including cholesterol) in the blood, abnormal glucose metabolism, and other clinical complications such as heart disease.

Potential interactions between HAART and medications used to treat drug addiction may decrease the effectiveness of either or both treatments. For example, methadone blood concentration drops as a result of the components in HAART therapy. There is currently research to determineif buprenorphine which is a treatment for opioid addictions has similar problems.

One issue for people treated with HAART is sticking to the medication regimen which is needed to benefit from HAART. Adherence can be particularly problematic for drug abusers with chaotic lifestyles, which can interfere with their ability to follow prescribed regimens. In addition, because HAART reduces viral load, some patients mistakenly believe that they do not need to adhere to the AIDS treatment regimen or that reduced viral load means elimination of the risk of transmitting HIV. This can unfortunately lead to a lack of regard for the high risk behaviors and the resuming of unsafe practices. Research has improved HIV/AIDS outcomes amoung IDU and has advanced discoveries for long term treatment of HIV/AIDS.

Lopinavir was developed by Abbott in an attempt to improve on the HIV/AIDS resistance and serum protein-binding properties of the company’s earlier protease inhibitor, ritonavir. Administered by itself lopinavir has too low of a bioavailability; but many HIV protease inhibitors can be boosted with low doses of ritonavir and this is the case with lopinavir. Abbott therefore pursued a strategy of co-administering lopinavir with sub-therapeutic doses of ritonavir, and lopinavir is only marketed as a co-formulation with ritonavir. Its the first HIV medication to not be offered individually.

Kaletra Lopinavir/ritonavir was approved for use by the FDA on September 2000, and 1 year later in Europe. Its patent will expire in the US on June 26, 2016.

Abbott was one of the first users of the APS, a synchrotron radiation light source at Argonne Nat. Lab. One early reseach project undertaken at the APS was HIV. Utilizing X ray crystallography researchers were able to find the points of attack of the HIV protease inhibitors, agents that prevent the breakdown of proteins. Protease inhibitors stop HIV from making new copies of itself by blocking the last step in the process, when the virus attempts to replicate – and out of that discovery came the drug Kaletra.

Abbott was one of the first users of the APS, a synchrotron radiation light source at Argonne Nat. Lab. One of the early research projects undertaken at the Advanced Photon Source was the Human Immunodeficiency Virus. Using X-ray crystallography, researchers found the points of attack of the HIV protease inhibitors – agents that block the breakdown of proteins. Protease inhibitors stop HIV from making new copies of itself by blocking the last step in the process, when the virus attempts to replicate – and out of that discovery came the drug Lopinavir.

Despite substantial advances in the treatment of human immunodeficiency virusHIV/AIDS infection, the estimated number of annual new HIV infections in the United States has remained at 40,000 for over 10 years. HIV prevention has mostly focused on persons who are not infected, in order to help them avoid becoming infected. However, further reduction of HIV transmission will require new strategies, including increased emphasis on preventing transmission by HIV-infected persons. HIV-infected persons who are aware of their HIV infection tend to reduce behaviors that might transmit HIV to others. Nonetheless, recent reports suggest that such behavioral changes often are not maintained and that a substantial number of HIV-infected persons continue to engage in behaviors that place others at risk for HIV infection.

Reversion to risky sexual behavior might be as important in HIV transmission as failure to adopt safer sexual behavior immediately after receiving a diagnosis of HIV. Unprotected anal sex appears to be occurring more frequently in some urban centers, particularly among young men who have sex with men (MSM). Bacterial and viral sexually transmitted diseases (STDs) in HIV-infected men and women receiving outpatient care have been increasingly noted, indicating ongoing risky behaviors and opportunities for HIV transmission. Despite the decline in syphilis infection rate in the general U.S. population, sustained outbreaks of syphilis among MSM, many of whom are HIV infected, continue to occur in some areas; rates of gonorrhea and chlamydial infection have also risen for this population. Increased STD rates amoung MSM show increased potential for HIV transmission, both these rates suggest ongoing risky sexual behavior, and because STDs increases HIV’s infectivity and susceptibility. Studies suggest that optimism about the effectiveness of highly active antiretroviral therapy (HAART) for HIV may be contributing to relaxed attitudes toward safer sex practices and increased sexual risk-taking by some HIV-infected persons.

Injection drug use also continues to play a key role in the HIV epidemic; at least 28% of AIDS cases among adults and adolescents with known HIV risk category reported to CDC in 2000 were associated with injection drug use. In some large drug-using communities, HIV seroincidence and seroprevalence among injection drug users (IDUs) have declined in recent years. The decline has been a result of several things, including a increased use of sterile needles, lower rates of needle sharing, shifts from injection to noninjection methods of using drugs, and the cessation of drug use. However, injection-drug use among young adult heroin users has increased substantially in some areas a reminder that, as with sexual behaviors, changes to less risky behaviors may be difficult to sustain.

Clinicians providing medical care to HIV-infected persons can play a key role in helping their patients reduce risk behaviors and maintain safer practices and can do so with a feasible level of effort, even in constrained practice settings. Clinicians can greatly affect patients’ risks for transmission of HIV to others by performing a brief screening for HIV transmission risk behaviors; communicating prevention messages; discussing sexual and drug-use behavior; positively reinforcing changes to safer behavior; referring patients for such services as substance abuse treatment; facilitating partner notification, counseling, and testing; and identifying and treating other STDs. These steps may also help to decreaste a patients’ risks of getting other STDs and bloodborne infections (e.g., viral hepatitis). Managed care plans can play an important role in HIV prevention by incorporating these recommendations into their practice guidelines, educating their providers and enrollees, and providing condoms and educational materials. In the context of care, prevention services might be delivered in clinic or office environments or through referral to community-based programs. Some clinicians have expressed concern that reimbursement is often not provided for prevention services and note that improving reimbursement for such services might enhance the adoption and implementation of these guidelines.

Each HIV infected patient who is entering into care should have a full medical history, physical, lab evaluation and counseling. This is to confirm the presenence of HIV, get historical and laboratory data, discuss treatment of HIV with patient, and initiate care as suggested by HIV primary care guidelines. Baseline data then is utilized to define management goals and future plans.

The following laboratory tests should be performed for a new patient during initial patient visits:

•  HIV antibody testing (if prior documentation not available) or if HIV RNA is undetectable (AI);
•  CD4 T-cell count (AI);
– HIV RNA (Viral Load);
•  Complete blood count, chemistry profile, transaminase levels, BUN and creatinine, urinalysis, screening test
for syphilis (e.g., RPR, VDRL, or treponema EIA), tuberculin skin test (TST) or interferon-? release assay
(IGRA) (unless there is a history of prior tuberculosis or positive TST or IGRA), anti-Toxoplasma gondii IgG,
hepatitis A, B, and C serologies, and Pap smear in women (AIII);
• Fasting blood glucose and serum lipids if the patient is considered at risk for cardiovascular disease and for
baseline evaluation before the start of ARV therapy and
• For patients who have pretreatment HIV RNA >1,000 copies/mL, genotypic resistance testing when the
regardless of whether or not a patient is going to begin therapy immediately they need to enter into care. For patients who
have HIV RNA levels of 500–1,000 copies/mL, resistance testing also may be considered, even though
amplification may not always be successful (BII). If therapy is deferred, repeat testing at the time of
antiretroviral initiation should be considered (CIII).

Patients living with HIV infection must often cope with multiple social, psychiatric, and medical issues that are best
addressed through a multidisciplinary approach to the disease. The evaluation also must include assessment of
substance abuse, economic factors (e.g., unstable housing), social support, mental illness, comorbidities, high-risk behaviors, and other factors that are known to impair the ability to adhere to treatment and to promote education about HIV Once evaluated, these factors should be managed accordingly.
Lastly,  risk behaviors and effective strategies to prevent HIV transmission. to others should be
provided at all a patient’s clinical visits.

HIV can be hard to diagnose, if you think you might have contracted hiv you should ge test as soon as possible. Symptoms often can take a long time to develop after the intial exposure to HIV, but common HIV/AIDS symptoms include thrush or chronic yeast infections, skin discoloration, easy bruising, nausea, vommiting, and exhaustion. As the bodies immune system starts to be damage more advanced symptoms can present as more severe OI’s. This includes chronic infections that don’t regularly happen in healthy indivduals and even some cancers. HIV tests are used to confirm the presence of anti HIV cells in your blood or saliva and not the actual virus. Advanced opportunistic infections begin to become prevalent as the immune systems CD4 cells drop below 200. HIV spread happens when infected bodily fluids enter your body. The most common occurances happen during sexual intercourse and the sharing of needles. Its important to always use condoms and practice safe sex. Condoms are effective at preventing the transmission of HIV as well as other STDs during sex. Practicing safe sex means using a condom every time. If you use drugs that are injected, always use clean needles and never share them. It is important to help raise awareness about HIV transmission, it plays a critical role in preventing HIV spread. Its important to get tested for HIV even if you think you are not infected, and if you are sexually active you should be routinely screened. Free HIV testing is often available, and some clinics perodically offer free HIV testing. HIV tests are simple to get, especially with the advent of rapid result test you can be tested and recieve your results within thirty minutes. The test is performed by taking a sample of saliva and does not even require blood to be drawn.

AIDS HIVwas first reported in the United States in 1981 and has since become a major worldwide epidemic. AIDS is caused by the human immunodeficiency virus, or HIV. By killing or damaging cells of the body’s immune system, HIV progressively destroys the body’s ability to fight infections and certain cancers. People diagnosed with AIDS may get life-threatening diseases called opportunistic infections. These infections are caused by microbes such as viruses or bacteria that usually do not make healthy people sick.

HIV Causes AIDS

Since 1981, more than 980,000 cases of AIDS have been reported in the United States to the Centers for Disease Control and Prevention (CDC). The CDC reports that 1 million Americans are likily infected with HIV, 1/4 of which are unaware of their infection. The epidemic is growing most rapidly among minority populations and is a leading killer of African-American males ages 25 to 44. The CDC reports that HIV/AIDS affects nearly 10x more African Americans and 3x more Hispanics then whites. In recent years, an increasing number of African-American women and children are being affected by AIDS/HIV.

HIV eliminates CD+ immune cells, which are cells crucial to maintaining the body’s immune system. As the virus attacks those cells, the person infected with HIV is less equipped to fight off infection and disease ultimately resulting in the development of AIDS.

Generally people who are infected with HIV can have the viruses for a realtively long period before the immune system starts to fail. There is a strong connection between HIV in the blood and the decline of CD4 cells and the onset of AIDS. Antiretroviral medicines can reduce the amount of virus in the body, preserve CD4+ T cells and dramatically slow the destruction of the immune system.